<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Copper Cu-64 dotatate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Copper Cu-64 dotatate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Copper Cu-64 dotatate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="129651" href="/d/html/129651.html" rel="external">see "Copper Cu-64 dotatate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54863498"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Detectnet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54816082"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F54842723"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic imaging:</b>
<b>IV:</b> 148 MBq (4 mCi); begin positron emission tomography (PET) scanning 45 to 90 minutes after completion of copper Cu 64 dotatate administration.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54842725"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F54842726"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F54842724"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use caution.</p></div>
<div class="block adr drugH1Div" id="F54820539"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (&lt;2%), vomiting (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F54816085"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54842714"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Cutaneous hypersensitivity reactions (eg, pruritus, rash) have been reported; usually reverse spontaneously or with symptomatic management. Rarely, angioedema and anaphylaxis have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation accumulation: Copper Cu 64 dotatate administration contributes to the patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in neuroendocrine tumors (NETs). Uptake may also be seen in other tumor types that express somatostatin receptors, other pathologic conditions (eg, thyroid disease, subacute inflammation), or normal physiologic variants (eg, uncinated pancreatic process). Uptake may require confirmation by histopathology or other assessments. The presence of NET tumors does not mean somatostatin receptors will not be visualized.</p></div>
<div class="block foc drugH1Div" id="F54863499"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Detectnet: 1 mCi/mL (1 ea) [contains alcohol, usp]</p></div>
<div class="block geq drugH1Div" id="F54863497"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54962696"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Detectnet Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mci/mL (per each): $4,620.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54842727"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV bolus over ~1 minute, followed by a saline flush. Immediately prior to administration use a dose calibrator to measure patient dose; use within 2 hours of calibration.</p>
<p style="text-indent:-2em;margin-left:2em;">Begin imaging prior to dosing with somatostatin analogs. For patients on a long-acting somatostatin, a 28-day wash-out period is recommended prior to imaging. For patients on a short-acting somatostatin, a 2-day wash-out period is recommended prior to imaging.</p>
<p style="text-indent:-2em;margin-left:2em;">Imaging should include whole body acquisition from skull vertex to midthigh. Begin positron emission tomography (PET) scanning 45 to 90 minutes after completion of copper Cu 64 dotatate administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should drink a sufficient amount of water to ensure adequate hydration prior to administration and in the first hours following administration and void frequently following administration to reduce radiation exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. When handling and administering, follow appropriate safety measures to minimize radiation exposure during administration; use waterproof gloves and effective shielding, including syringe shields.</p></div>
<div class="block use drugH1Div" id="F54816084"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> Use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors in adults.</p></div>
<div class="block mst drugH1Div" id="F54842710"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Copper Cu 64 dotatate may be confused with Gallium Ga 68 dotatate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and health care personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54846653"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54846650"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: May diminish the diagnostic effect of Copper Cu 64 Dotatate. Management: Imaging with copper Cu 64 dotatate positron emission tomography (PET) should be performed just prior to dosing with somatostatin analogs. If on somatostatin analogs, stop long-acting agents 28 days before, and short-acting agents 2 days before, imaging.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54842712"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F54842711"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. Elective diagnostic procedures should be delayed until after delivery (ACR-SPR 2018; SNM 2010).</p></div>
<div class="block brc drugH1Div" id="F54842713"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if copper Cu 64 dotatate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that breastfeeding be interrupted for 12 hours after administration to decrease potential radiation exposure to the breastfed infant. Elective diagnostic procedures should be delayed until breastfeeding has stopped (SNM 2010). Women who are breastfeeding and caring for individuals undergoing nuclear medicine procedures do not need any additional precautions (ABM [Mitchell 2019]).</p></div>
<div class="block pha drugH1Div" id="F54842718"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Copper Cu 64 dotatate is a radioactive diagnostic agent. Cu 64 dotatate binds to cells that express somatostatin receptors, including malignant neuroendocrine cells, which overexpress somatostatin type 2 (sstr2) receptors. Copper Cu 64 is a beta+ emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging. Tumors that do not express somatostatin receptors will not be visualized by imaging.</p></div>
<div class="block phk drugH1Div" id="F54842719"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Extensive to all somatostatin type 2 (sstr2)-expressing organs (including adrenal glands, kidney, liver, pituitary glands, and spleen).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Copper Cu 64 dotatate decays with a half-life of 12.7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (16% to 40% over 6 hours).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American College of Radiology (ACR), Society for Pediatric Radiology (SPR). ACR–SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation (resolution 39). https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Pregnant-Pts.pdf?la=en. Revised 2018.</div>
</li>
<li>
<div class="reference">
                  Detectnet (copper Cu 64 dotatate) injection [prescribing information]. Maryland Heights, MO: Curium US LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31107104">
<a name="31107104"></a>Mitchell KB, Fleming MM, Anderson PO, Giesbrandt JG; Academy of Breastfeeding Medicine. ABM clinical protocol #30: radiology and nuclear medicine studies in lactating women. <i>Breastfeed Med</i>. 2019;14(5):290‐294. doi:10.1089/bfm.2019.29128.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/copper-cu-64-dotatate-drug-information/abstract-text/31107104/pubmed" id="31107104" target="_blank">31107104</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Society of Nuclear medicine (SNM). Society of Nuclear Medicine procedure guideline for general imaging. Version 6.0. http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/General_Imaging_Version_6.0.pdf. Revised 2010.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129471 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
